Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.

ABSTRACT:

Background

Rabies kills around 60 000 people each year. ChAdOx2 RabG, a simian adenovirus-vectored rabies vaccine candidate, might have potential to provide low-cost single-dose pre-exposure rabies prophylaxis. This first-in-human study aimed to evaluate its safety and immunogenicity in healthy adults.

Methods

We did a single-centre phase 1 study of ChAdOx2 RabG, administered as a single intramuscular dose, with non-randomised open-label dose escalation at the Centre for Clinical Vaccinology and Tropical Medicine, Oxford, UK. Healthy adults were sequentially allocated to groups receiving low (5 × 10⁹ viral particles), middle (2·5 × 10¹⁰ viral particles), and high doses (5 x 10¹⁰ viral particles) of ChAdOx2 RabG and were followed up to day 56

SUBMITTER: Jenkin D 

PROVIDER: S-EPMC7614839 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature